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tumor-initiating cells with stem cell properties are believed 
to sustain the growth of gliomas, but proposed markers such 
as Cd133 cannot be used to identify these cells with sufficient 
specificity. We report an alternative isolation method purely 
based on phenotypic qualities of glioma-initiating cells (GICs), 
avoiding the use of molecular markers. We exploited intrinsic 
autofluorescence properties and a distinctive morphology to 
isolate a subpopulation of cells (FL1+) from human glioma or 
glioma cultures. FL1+ cells are capable of self-renewal  
in vitro, tumorigenesis in vivo and preferentially express 
stem cell genes. the FL1+ phenotype did not correlate with 
the expression of proposed GIC markers. our data propose an 
alternative approach to investigate tumor-initiating potential 
in gliomas and to advance the development of new therapies 
and diagnostics.
Human gliomas are primary neoplasms of the central nervous 
system that grow diffusely, show different grades of local aggres-
siveness and display histological and immunohistochemical 
features of glial lineages or less differentiated neural progenitor 
cells1–3. Although the exact cellular origin of gliomas remains 
unclear2,3, it has been proposed that only a fraction of cancer 
cells with stem cell properties, usually named cancer stem cells, 
has true tumorigenic potential and constitutes a discrete reservoir 
of glioma-initiating cells4,5. Glioma-initiating cells initially had 
been identified as CD133+ cells6,7, but recent studies demonstrate 
a relative lack of specificity of this marker8–11. Also, some studies 
have questioned the existence of a cellular hierarchy dominated 
by cancer stem cells in solid tumors or alternatively have shed 
doubt on their supposed rarity12,13. Despite current controver-
sies, there is general agreement that tumors are heterogeneous 
populations of cells, some of which have a superior tumor initiat-
ing and propagating ability. There is therefore a need for reliable 
methods to identify, isolate and characterize the entire glioma-
initiating cell reservoir, even if all cells in this set do not neces-
sarily have bona fide stem cell properties or express homogenous 
molecular markers.
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Here we show that the combination of a distinct morpho-
logy and autofluorescence emission can be used to identify a 
subpopulation of glioma cells with self-renewal ability in vitro 
and tumor- initiating and propagating capacity in vivo. Cells in 
this population have enhanced proliferative activity and prefer-
entially express stem cell–related genes. By avoiding the use of 
molecular markers and relying on general phenotypic properties 
correlating with tumorigenicity, our results offer a simple 
approach for identifying glioma-initiating cells that might be 
efficiently exploited to understand the molecular mechanisms 
governing tumor growth.
resuLts
Identification of a new glioma cell subpopulation
A subpopulation of human glioma cells displays autofluorescence 
emission around 520 nm (in the FL1 channel) upon laser excitation 
at 488 nm (Supplementary Table 1 and Supplementary Fig. 1). 
Cells in this fraction, hereafter called FL1+, can be detected 
both by fluorescence-activated cell sorting (FACS) or fluores-
cence microscopy in glioma cell cultures and in freshly dissoci-
ated glioma tissue (Fig. 1a–d and Supplementary Tables 2–4). 
All tumors are labeled according to their type and World 
Health Organization (WHO) grade and numbered as described 
in Supplementary Table 2. The microscopic analysis of FL1+ 
cells confirmed that they were large agranular cells with a very 
high nuclear:cytoplasmic ratio (Fig. 1c) correlating with the high 
forward scatter and a low side scatter in the FACS analysis. In serum-
free conditions (stem cell culture conditions), glioma cells form 
floating colonies enriched in glioma-initiating cells (glioma-
spheres)14. Analysis of gliomasphere cultures from different tumors 
showed varying percentages of FL1+ cells (Supplementary Table 3, 
n = 10 cultures), which remained stable over 20 passages in vitro 
(Supplementary Fig. 2). Analysis of freshly dissociated human 
gliomas of different malignancy grade and subtype also revealed 
the presence of a relatively rare FL1+ cell population (Fig. 1c  
and Supplementary Table 4; n = 26 tissues) displaying on aver-
age lower fluorescence intensity (mean of intensity < 102) than 
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that observed in gliomasphere cultures (mean of intensity > 102). 
As freshly dissociated cells from tumors were more hetero-
geneous than cells from gliomasphere cultures, for isolation of 
FL1+ cells from fresh tissue we adjusted the FACS gating, taking 
into account cell size, granularity and fluorescence according to 
the characteristics of the gliomasphere FL1+ population.
differentiation conditions affect FL1+ cells
Induction of differentiation in gliomaspheres results in cellular 
changes including cell adherence and expression of neural dif-
ferentiation markers4,14–16. When plated under differentiation 
conditions (serum-rich medium), purified FL1+ cells and viable 
nonfluorescent (FL10) cells expressed a similar pattern of dif-
ferentiation markers such as TUJ1, MAP2, GFAP and NESTIN 
(Supplementary Fig. 3) when examined 4–8 d after plating. After 
10 d of differentiation, however, cells with FL1+ characteristics 
could no longer be detected in cultures derived from sorted FL1+ 
cells, in contrast to matched FL1+ samples cultured in stem cell 
conditions (Fig. 1e). The subsequent transfer of differentiated 
cultures into stem cell culture conditions did not reconstitute FL1+ 
properties such as autofluorescence or sphere formation (Fig. 1e). 
Similarly, when we plated fresh glioma-derived cells in serum-rich 
conditions, the autofluorescent subpopulation and its spherogenic 
ability was irreversibly lost (Supplementary Fig. 4). The fact that 
FL1+ cells were only present in stem cell culture conditions and 
were lost upon induction of differentiation suggests that FL1+ cells 
may have properties similar to those of stem cells.
self-renewal of FL1+ cells
As self-renewal is a property of stemness in normal tissue and has 
also been used to characterize cancer stem cells17, we tested the 
ability of FL1+ cells to self renew in clonogenic assays. Single-cell 
plating of sorted FL1+ and FL10 cells either from fresh dissociated 
glioma tissues or from glioma cell cultures revealed that FL1+ cells 
have a superior capacity to self-renew than FL10 cells (Fig. 2a,b). 
We then measured the self-renewal ability of individual FL1+ and 
FL10 clones over several successive cell passages. Whereas FL1+ 
clones retained spherogenic potential for at least five passages, 
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Figure 1 | Glioma tumors and cell cultures contain 
an autofluorescent population. (a) FACS analysis 
of primary glioblastoma multiforme (GBM)-16 
gliomasphere culture. Autofluorescence was 
detected in the FL1 channel (515 ± 5 nm or  
530 ± 15 nm). P1 (green) gated viable FL1+ cells;  
P2 (blue) gated viable FL10 cells. Fluorescent and 
nonfluorescent cells in the FL1+ population (P1) are represented by P4 and 
P3, respectively. FL2 channel, excitation 556 nm and emission at 570 ± 
10 nm. Fluorescent and nonfluorescent cells in the FL10 cell compartment 
(P2) are represented by P6 and P5, respectively. Black dots represent the 
nongated population and include dead cells. (b) Two-photon image of a 
live gliomasphere (primary GBM-17). Green is autofluorescence. (c) FACS 
analysis of freshly dissociated primary GBM-16 cells. P9 (yellow) represents 
a small population with low side scatter (SSC) and forward scatter (FSC), 
which was only detected in fresh primary human sample or in tissue 
from mice bearing tumors. (d) Confocal image of a single FL1+ cell after 
prospective sorting of fresh glioma tissue. DAPI (blue) stains the nucleus, 
and green shows autofluorescence. (e) FACS analysis of secondary GBM-1 cells cultured in stem cell medium (top), plated in differentiation medium 
(middle), and subsequently transfered into stem cell medium to test for ‘reversiblity’ (bottom). Scale bars, 50 µm (b,e) and 7.5 µm (d).
Figure 2 | FL1+ cells display exclusive self-renewal 
abilities. (a) Quantification of single cells that form 
secondary spheres after sorting and clonal plating 
of FL1+ and FL10 cells from the indicated samples. 
Errors bars, s.d. (n = 3); *P < 0.5. GBM,  
glioblastoma multiforme WHO grade IV; O.A III, 
oligoastrocytoma WHO grade III. (b) Quantification 
of single cells that form primary clones after 
isolation of FL1+ and FL10 cells from the indicated 
samples. *P < 0.5. O.A II, oligoastrocytoma WHO 
grade II; O.G. III, oligodendroglioma WHO grade 
III. (c) Quantification of viable clones after serial 
passage (up to 5) of cells derived from a single 
FL1+ or FL10 cell. (d) Phase-contrast images of an 
FL1+ and an FL10 clone during serial passage. Scale 
bar, 50 µm (left) and 100 µm (right three panels).
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FL10 clones were lost between passage 3 and 4 with no clone capable 
of sustaining new sphere formation (Fig. 2c and Supplementary 
Table 5). FL1+ spheres were larger, floating and apparently health-
ier than the partially attached and undersized FL10 clones (Fig. 2d). 
Moreover, FL10 derived clones did not contain any FL1+ cells, 
whereas isolated FL1+ cells could generate both FL1+ and FL10 
cells in passaged gliomaspheres (Supplementary Fig. 5).
expression of stemness-related genes in FL1+ cells
Several stem-cell and progenitor-cell gene expression profiles 
have been identified in gliomas or glioma-initiating cells18–20. 
To understand the molecular mechanisms underlying the 
selective stemness phenotype of FL1+ glioma cells, we quan-
tified the expression of 14 selected18 stemness-related genes 
in FL1+ and FL10 cells from four different gliomas. The only 
genes expressed more than twofold in FL1+ cells were NANOG, 
POU5F1 (also known as OCT4), SOX2 and NOTCH1 (Fig. 3a and 
Supplementary Table 6). FACS and confocal imaging analysis of 
stemness-related proteins corresponding to the above-mentioned 
genes revealed a preferential but not exclusive expression in FL1+ 
cells (Fig. 3b,c and Supplementary Fig. 6). Although the majority 
of KI67+ cells were confined to the FL1+ cell fractions, FL10 cells 
also expressed KI67 (Fig. 3b,c and Supplementary Fig. 6f), sug-
gesting that FL10 cells were viable and proliferated to some extent. 
We found a relatively low percentage of CD133+ cells in both FL10 
and FL1+ cell compartments (Fig. 3d, Supplementary Fig. 7 and 
Supplementary Table 7). Conversely, sorted CD133+ cells were 
distributed in both FL10 and FL1+ cell compartments (Fig. 3e and 
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Figure 3 | Expression of stemness related 
genes in FL1+ cells. (a) Representative reverse 
transcriptase (RT)-PCR analysis of gene expression 
in FL1+ and FL10 cells. (b) The ratio of protein 
levels in FL1+ cells versus FL10 cells is plotted 
for the indicated proteins, quantified by FACS. 
(c) Representative confocal images of primary 
glioblastoma multiforme (GBM)-3 gliomaspheres 
stained with the indicated stemness markers (red). 
Autofluorescence (green) and DAPI staining (blue) 
are also shown. Scale bar, 65 µm. (d) FACS analysis 
of cells dissociated from primary GBM-2 cell culture 
and stained for CD133 (left; gating is as in  
Fig. 1a) and expression of CD133 in the FL1+ and 
FL10 cell populations (right). Red dots represent 
CD133+ cells. Upper left, CD133+ FL10; upper 
right, CD133+ FL11; lower left, CD133− FL10; and 
lower right, CD133– FL11. Black dots represent 
the nongated population and percentages in each 
quadrant are relative to total viable cells. (e) FACS 
analysis of cells dissociated from primary GBM-2 
cell culture and stained for CD133. Cells were gated 
on viable cells (P0; left). Expression of CD133 in 
viable glioma-initiating cells (P0) gated), P3 and 
P4 gate the CD133+ and CD133− cell populations, 
respectively (middle). Distribution of the FL1+ and FL10 cells from the CD133+ cell population (P3) (right). Percentages in each quadrant are relative to total 
viable cells. FL3 channel: excitation at 556 nm and emission at 570 ± 15 nm as shown in supplementary table 1. 
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Figure 4 | FL1+ cells initiate and sustain 
tumor growth in vivo. (a) Representative 
magnetic resonance images of mice brains 
after implantation with FL1+ or FL10 cells from 
primary glioblastoma multiforme (GBM)-3 cell 
culture before (T2-weighted fast-spin echo) and 
after contrast (T1-weighted fast-spin echo with 
gadolinium contrast agent). Scale bar, 0.25 cm. 
Hematoxylin and eosin (H&E)-stained  
images and FL1 autofluorescent (green),  
DAPI-stained (blue) images of implanted brain 
slices are also shown; scale bars, 90 µm.  
(b) Fluorescence images of brain sections 
derived from FL1+ implanted mice (primary 
GBM-3) and immunostained for the indicated 
markers (red). FL1 autofluorescence (green) 
and DAPI staining (blue) are also shown. 
Scale bars, 40 µm. (c) Analysis of mice after 
injection with different numbers of sorted FL1+ 
and FL10 cells from the indicated samples.
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Figure 5 | Tumorigenic capacity of FL1+ cells. (a) Representative magnetic resonance images of mice brains after implantation with FL1+ or FL10 cells 
prospectively isolated from primary glioblastoma multiforme (GBM)-12, precontrast T2-weighted fast-spin echo and postcontrast (T1-weighted fast-spin 
echo with gadolinium contrast agent). Scale bar, 0.25 cm. Hematoxylin and eosin (H&E)-stained images and FL1 autofluorescent (green), DAPI-stained 
(blue) images of implanted brain slices are also shown; scale bars, 90 µm. (b) Fluorescence images of brain sections derived from FL1+ cell–implanted 
mice (primary GBM-12) and immunostained for the indicated markers (red). FL1 autofluorescence (green) and DAPI staining (blue) are also shown. 
Scale bars, 40 µm.
Supplementary Table 8). Statistical analysis (paired t-test) of 
the percentage of FL1+ cells and CD133+ cells as determined by 
FACS in fresh primary glioblastoma multiforme (P = 0.69, R2 = 
0.094, n = 4) and gliomasphere cultures (P = 0.58, R2 = 0.094, 
n = 5) confirmed that there was no correlation between the FL1+ 
phenotype and the expression of CD133, suggesting that CD133 
alone might not be sufficient to fractionate cancer-initiating 
and non-cancer-initiating cells.
FL1+ cells were tumorigenic in vivo
To test whether glioma-initiating cells originated only from the 
FL1+ population, we intracranially injected sorted FL1+ or FL10 
cells from fresh tissue or from two primary and one secondary gliob-
lastoma multiforme–derived gliomasphere cultures (Figs. 4 and 5 
and Supplementary Table 9). When cells to be injected were 
isolated from gliomasphere cultures, all mice injected with FL1+ 
cells, even with a load of 103 cells, exhibited substantial weight 
loss and neurological symptoms within few weeks, correlating 
with intracranial tumors observed on magnetic resonance images 
and histological sections (Fig. 4 and Supplementary Fig. 8). We 
detected no tumors in FL10 cell–injected mice even at a 105 intra-
cranial cell load after more than three months (Supplementary 
Table 9), except for one experiment, which subsequently revealed 
the presence of FL1+ cells, potentially because of a residual con-
tamination of FL1+ cells during FACS. Upon injection of cells 
obtained from fresh glioma, only the mice implanted with the 
FL1+ cells developed neurological symptoms by four months, 
which correlated with a massive infiltrative glioma (Fig. 5). Serial 
transplantation of freshly isolated FL1+ cells confirmed that the 
tumorigenic potential was exclusively confined to the FL1+ cell 
population (Supplementary Table 10). Implantation of as few as 
3,000 FL1+ cells was sufficient to initiate tumorigenesis within 
three months (data not shown). On histological sections, FL1+ 
cell–induced tumors showed FL1 autofluorescence and contained 
a higher proportion of NESTIN+ and KI67+ cells compared to 
GFAP+, TUJ1+ cells (Fig. 5b and Supplementary Fig. 8). The 
human origin of the tumors was confirmed by human MHC-I 
staining (Supplementary Fig. 9). When we analyzed brains of 
injected mice after dissociation, we found FL1+ cells only in FL1+ 
cell–injected brains (Supplementary Fig. 9). Plating of disso-
ciated cells resulted in the formation of many large spheres from 
FL1+ tumors within 2 or 3 d, in contrast to cultures derived from 
FL10 cell–injected brains (Supplementary Fig. 9). These data sug-
gest that a selection strategy based on phenotype can identify, in 
both glioma and glioma cultures, a subpopulation of glioma cells 
with exclusive in vivo tumorigenic potential.
dIsCussIon
Our data suggest that self-renewing and tumor-initiating glioma 
cells have a distinct morphology and autofluorescence, which 
allows their identification and isolation from non-tumorigenic 
glioma cells independently of CD133. FL1+ cells were enriched 
for stemness-related genes, were multipotent, could generate FL10 
cells and could self-renew over time (Supplementary Fig. 10). 
Moreover, as clonal gliomaspheres derived from FL1+ cells con-
tained a mixed population of FL1+ and FL10 cells, FL10 cells 
should logically be derived from FL1+ cells either by asymmetric 
division or by loss of properties associated with autofluorescence 
in some FL1+ cells. Because FL10 cell–derived cultures did not 
yield any FL1+ cells, FL10 cells may be committed tumor pro-
genitors or differentiating cells that have lost their self-renewal 
and tumorigenic properties. We are currently studying the dif-
ferentiation potential of FL10 cells. They are not cancer-initiating 
cells as they unambiguously do not have long-term self-renewal 
properties in vitro and are not tumorigenic in vivo. However, 
when plated under conditions that promote differentiation, FL10 
cells expressed differentiation markers, as did FL1+ cells under 
similar culture conditions. Thus the FL10 population may include 
progenitor cells in addition to more differentiated cancer cells.
We do not yet understand the molecular basis of the autofluores-
cence in FL1+ cells. Several studies have linked autofluorescence 
with the cell cycle and/or cellular metabolic activity, such as the 
intracellular NAD/NADPH status or mitochondrial flavin con-
tent21–23. Our preliminary data suggest that autofluorescence in 
FL1+ cells may reflect higher metabolic and proliferative activity 
(data not shown). In this respect, the relatively low autofluores-
cence levels and rarity of the FL1+ population in vivo, relative to 
what we observed in in vitro culture, may indicate a more qui-
escent state of FL1+ cells when growing in their natural tumor 
environment with lower oxygen levels, growth factor supply and 
glucose concentrations than those present in vitro.
Present knowledge of other normal and cancer tissues such 
as the hematopoietic system indicates that stem cells or early 
progenitor populations are rarely defined by only one but rather 
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by a combination of molecular markers24. Notably, none of the 
stemness genes (including CD133) that potentially could be 
used as a functional cancer stem cell marker, was exclusively 
restricted to the FL1+ population as expression of all tested genes 
was also detectable in FL10 cells. Moreover, ‘stemness’, and in 
particular cancer stemness, might well be an elusive property 
that is not defined by invariable molecular markers but may 
have less stable molecular configurations that change with time 
and environmental context12,13,25–27. Differences between TICs 
and other tumor cells may not be as clear-cut as in normal 
tissues, in which a stringent hierarchy and strictly balanced 
asymmetric division guarantees tissue integrity28,29. As they are 
genetically altered, cancers might contain a spectrum of ‘inter-
mediate’ tumor cells with various tumorigenic potencies and 
more or less aberrant differentiation states3,26. It may therefore 
be possible to consider cancer stemness in a given subpopulation 
or in single cells as a property with variable expressivity rather 
than a strictly committed on or off state with obligatory expres-
sion of defined markers.
Altogether, our data show that a subpopulation of glioma cells 
have an identifiable cellular phenotype strongly correlated with 
stemness and tumorigenic capacity and can be isolated without 
the use of molecular markers. Exploiting these properties may be 
more suitable to capture the dynamic complexity of tumor initiat-
ing cells and allow the identification of new therapeutic targets.
methods
Methods and any associated references are available in the online 
version of the paper at http://www.nature.com/naturemethods/.
Note: Supplementary information is available on the Nature Methods website.
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Processing, clonogenic and differentiation assays on tumors 
and gliomasphere cultures. Primary brain tumors were obtained 
following approved institutional (HUG) protocols and written 
consent was obtained from all patients. Cells were cultured 
as in4,8. Media and growth factors were renewed once a week. 
Primary spheres are those spheres formed after fresh isolation of 
cells from tumors. Secondary spheres are the second generation of 
spheres generated from dissociated primary spheres. Sphere for-
mation was assessed as reported18 and presented as the percentage 
of clones derived from the initial number of cells plated. Self-
renewal ability was monitored by dissociating spheres mechani-
cally and transferring dissociated cells along successive passages 
as described previously8. Differentiation assays were performed 
as described previously15.
FACS analysis of cells using morphology, autofluorescence 
and CD133 staining. Fresh glioma cells or dissociated cells 
from gliomaspheres cultures were adjusted at a concentration of 
1 million cell per ml in 1× PBS (pH 7.4) before analysis or sort-
ing either on Beckton Dickinson FACScan or FACSVantage or 
AriA (BD Bioscience). In gliomasphere cultures, FL1+ cells were 
selected using the intersection of P1 and P4 and FL10 cells were 
selected using the intersection of P2 and P5 as shown in Figure 1a. 
For sorting from fresh glioma, the morphology and relatively 
low levels of fluorescence of the cells were taken into account for 
adjusting the gating by also incorporating cells with lower FL1 
signal after selecting for appropriate morphology (low SSC and 
high FSC), that is, FL1+ were selected using the intersection of P1 
and P3 and FL10 were selected using the intersection of P2 and 
P5 (Fig. 1c). Characteristics of FL1 autofluorescence were evalu-
ated by excitation with additional lasers at different wavelengths: 
488 nm (Can, Vantage), 532 nm (Aria) 546 nm (Sorter), 632 nm 
(Calibur) (Supplementary Table 1 and Supplementary Fig. 1). 
CD133 staining and expression level analyses were performed 
as described previsouly8. Cell viability was tested by addition of 
trypan blue (Sigma) at 1/1,000 dilution. FACS data analysis was 
performed using CellQuest and Diva software.
Statistical analyses. Paired t-test, correlation and linear regres-
sion were done using GraphPad Prism. Experiments were carried 
out in triplicate for each assay on each individual gliomasphere 
culture mentioned.
Antibodies. Mouse anti-KI67 (Chemicon Int.), goat anti-
NOTCH1 (Santa Cruz), mouse anti-Integrinβ1 (Chemicon 
Int.), rabbit anti-PDGFRα (Spring Bioscience), mouse anti-
MAP2 (Chemicon Int.), mouse anti-VWB (von willebrand, 
Dako), mouse anti-NESTIN (R&D systems), rabbit anti-GFAP 
(Sigma), goat anti-NANOG (R&D systems), mouse anti-SOX2 
(R&D systems), rabbit anti-OCT4 (Abcam), mouse anti-TUJ1 
(Covance), goat anti-NOTCH1 (Santa Cruz) mouse anti-HLA 
A-B-C (BD Pharmigen), anti-mouse Alexa Fluor 555–conjugated 
secondary antibodies (Molecular Probes), anti-goat-Cy3 (Jackson 
ImmunoResearch Laboratories) or Alexa Fluor 647–conjugated 
(Molecular Probes) and anti-rabbit-Cy3–conjugated (Jackson 
ImmunoResearch Laboratories). DAPI (Sigma) was only used to 
stain nucleus and was added with secondary antibodies.
Immunochemistry and confocal microscopy. Gliomaphere 
stainings were performed in suspension without any sphere dis-
sociation. After fixation using 4% (wt/vol) PFA, gliomaspheres 
were incubated with 1× PBS with 1% (wt/vol) BSA and 0.1% 
(wt/vol) TritonX-100 for intracellular protein or without deter-
gent for membrane receptor protein. Antibodies were diluted 
in 1× PBS with 1% BSA and incubated either overnight at 4 °C 
under rotation with primary antibodies or for 1 h at room tem-
perature (20–22 °C) with secondary antibodies. For microscopy, 
gliomasphere were mounted between glass slide and coverslip 
before analysis on a LSM-510 Meta confocal microscope (Zeiss). 
For phase-contrast imaging on adherent and floating cultures, 
images were taken using the Openlab microscope (Zeiss). Image 
quantification and three-dimensional reconstruction were 
processed using the Imaris software, and quantified using the 
Metamorph software.
RNA extraction, RT-PCR and quantitative RT-PCR. Total RNAs 
were extracted using the RNAqueous-Micro kit (Ambion). Reverse 
transcription was performed using Superscript II (Invitrogen). 
Quantitative RT-PCR reactions were performed using the SYBR 
Green PCR master mix (Applied Biosystems) and samples were 
run on a 7900HT sequence detection system machine (Applied 
Biosystems). Primer sequences are available in ref. 18 and 
Supplementary Table 11. GAPDH, TUBG1 and EEF1A1 were 
used as control genes.
Mouse intracranial grafts and in vivo tumor imaging by MRI. 
Experimental procedures involving mice were approved by 
the Etat de Genève, Service Vétérinaire, authorization number 
1007/3337/2. Mouse intracranial xenografts were performed as 
described previously18. The mice were anesthetized during the 
entire MRI experiment with isofluorane. The magnetic resonance 
images were acquired on an MRI System (Varian Scientific) inter-
faced to 14.1-Tesla magnet with a 26-cm horizontal bore (Magnex 
Scientific). A home-built 14 mm diameter two-loop quadrature 
coil was used both for radio frequencey (RF) excitation and signal 
reception. The MRI protocol involved a precontrast T2-weighted 
fast-spin echo scan (a repetition time of 5 s, an effective echo time 
of 52 ms, a slice thickness of 0.6 mm, field of view = 24 × 24 mm2, 
a 2562 matrix size and eight echoes per scan) and a postcontrast 
T1-weighted spin echo scan (a repetition time of 380 ms, an echo 
time of 17 ms and the same geometrical parameters) performed 
after intraperitoneal Gd administration (150 µl of Gadovist 1.0 
which correspond to 5 µl of reagent per gram of weight).
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